Harmony Biosciences (HRMY) News Today

Versor Investments LP purchased a new stake in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY - Free Report) during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund purchased 18,210 shares of the company's stock, valued at approximately $54

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the nine research firms that are presently covering the stock, MarketBeat Ratings reports. Two investment analysts have rated the stock with a sell recommendation a

Hennion & Walsh Asset Management Inc. grew its stake in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY - Free Report) by 214.1% during the second quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 44,945 shares of the company's stock aft

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY - Free Report) - Equities research analysts at Cantor Fitzgerald raised their FY2024 earnings per share estimates for shares of Harmony Biosciences in a research note issued to investors on Wednesday, August 7th. Cantor Fitzgerald analyst C. Duncan

Harmony Biosciences (NASDAQ:HRMY) Trading 11.5% Higher

Needham & Company LLC restated a "buy" rating and issued a $52.00 target price on shares of Harmony Biosciences in a report on Tuesday.

Vanguard Group Inc. reduced its position in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY - Free Report) by 1.3% in the 1st quarter, according to its most recent filing with the SEC. The fund owned 3,628,225 shares of the company's stock after selling 46,539 shares during the period. Vanguard Gro

Janus Henderson Group PLC lifted its position in shares of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY - Free Report) by 1,011.7% in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 185,083 shares of the company's stock aft

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY - Get Free Report) has earned a consensus rating of "Moderate Buy" from the nine research firms that are presently covering the company, Marketbeat.com reports. Two equities research analysts have rated the stock with a sell recommendation and seven h

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY - Free Report) - Equities researchers at Cantor Fitzgerald cut their FY2024 EPS estimates for shares of Harmony Biosciences in a research note issued to investors on Wednesday, July 24th. Cantor Fitzgerald analyst C. Duncan now forecasts that the co

LSV Asset Management grew its holdings in shares of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY - Free Report) by 346.5% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 335,146 shares of

Harmony Biosciences (NASDAQ:HRMY) Stock Price Up 4.1%

Shares of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY - Get Free Report) have earned an average recommendation of "Moderate Buy" from the nine research firms that are currently covering the company, Marketbeat.com reports. Two research analysts have rated the stock with a sell recommendation an

Hedeker Wealth LLC bought a new position in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY - Free Report) during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 78,223 shares of the company's stock, valued

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY - Free Report) - Equities researchers at Cantor Fitzgerald increased their FY2024 EPS estimates for Harmony Biosciences in a research report issued to clients and investors on Monday, July 1st. Cantor Fitzgerald analyst C. Duncan now anticipates tha

Harmony Biosciences (NASDAQ:HRMY) Stock Price Down 2.9%

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY - Get Free Report) was the recipient of a large growth in short interest during the month of June. As of June 15th, there was short interest totalling 8,130,000 shares, a growth of 17.1% from the May 31st total of 6,940,000 shares. Based on an average trading volume of 383,000 shares, the days-to-cover ratio is presently 21.2 days. Approximately 26.5% of the shares of the stock are sold short.

Needham & Company LLC reissued a "buy" rating and set a $52.00 target price on shares of Harmony Biosciences in a report on Monday.

Citigroup initiated coverage on shares of Harmony Biosciences in a report on Friday. They set a "buy" rating and a $48.00 price objective on the stock.

Franklin Resources Inc. bought a new position in shares of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY - Free Report) in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor bought 27,136 shares of the company's stock, valued at approximately $876,0

Dimensional Fund Advisors LP reduced its stake in shares of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY - Free Report) by 6.1% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 736,268 shares of the compa

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY - Get Free Report) was the recipient of a large increase in short interest during the month of May. As of May 15th, there was short interest totalling 7,090,000 shares, an increase of 5.5% from the April 30th total of 6,720,000 shares. Approximately 23.1% of the shares of the company are sold short. Based on an average trading volume of 415,000 shares, the short-interest ratio is presently 17.1 days.

Charles Schwab Investment Management Inc. boosted its stake in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY - Free Report) by 9.7% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 319,167 shares of the company's sto

Great Lakes Advisors LLC lessened its position in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY - Free Report) by 49.7% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 141,301 shares of the company's stock after selling 139,867 shares

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY - Get Free Report) has been given an average recommendation of "Moderate Buy" by the eight research firms that are currently covering the firm, Marketbeat.com reports. Two research analysts have rated the stock with a sell recommendation and six have

LSV Asset Management bought a new stake in shares of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund bought 75,053 shares of the company's stock, va